Mast Therapeutics (MSTX) PT Raised at Piper Jaffray Following Sickle Cell Conference; Sees 100% Upside

Piper Jaffray analyst Edward Tenthoff lifted his price target on Overweight-rated Mast Therapeutics (NYSE: MSTX) to $1.20 (from $1.00) following yesterday's Piper Jaffray sponsored the 3rd Annual Sickle Cell Disease Therapeutics Conference.

"Prominently featured was Mast Therapeutics' MST-188, which is currently enrolling the 388-patient Phase III EPIC trial to shorten vaso-occlusive crisis (VOC)," Tenthoff notes.

He also highlighted:

• Phase III EPIC Trial Enrollment On Track
• Phase II ALI Study Underway.
• MST-188 Heart Failure Potential.
• Encouraging Phase II AIR001 PAH Data

For an analyst ratings summary and ratings history on Mast Therapeutics click here. For more ratings news on Mast Therapeutics click here.

Shares of Mast Therapeutics closed at $0.59 yesterday.

You May Also Be Interested In

• Tesla (TSLA) PT Lowered to $120 at HSBC on 'concerns about the timing and scale of prospects'
• GATX Corp. (GATX) PT Raised to $137 at TD Cowen
• Wayfair (W) PT Raised to $55 at TD Cowen